The Head of Research and Development at Radiant Life Technologies Dr Arzhan Surazakov, PhD., together with a Professor of Microbiology and Virology Prof. Oksana Gizinger and Dr Anna Klassen, specialising in laser therapy recently published a paper that suggests that this immune exhaustion is caused by an energy deficit in immune cells as a result of the body not having sufficient functional energy reserves to support the rapid rise of immune related energy expenditure. The paper has been published by the Journal of Photochemistry and Photobiology and PubMed Central.
Read the full paper here.
Researchers note that the total energy cost of the immune system in an active state is about 20% higher than normal (when resting and inactive). If a person has pre-existing chronic conditions, the body’s immune response can be limited because of reduced functional reserve in the body. In COVID-19 this failure of the immune system to contain infection rapidly leads to uncontrolled viral spread that leads to a so-called cytokine storm or hyperactivation of the immune response and ultimately acute respiratory distress syndrome, heart, kidney and other organ damage and ultimately death.
Download the coMra e-book for more information on coMra therapy
Cells in the body absorb energy, such as from glucose and then convert it into a form useable by the body, an organic compound called ATP. However, the thermodynamic efficiency of this conversion is quite low and could be a limiting factor in cell metabolism. Numerous studies have shown significantly increased ATP production after cells are irradiated with low-level infrared laser. This is the basis for what we call coMra therapy, which combines magnetism, coloured light and ultrasound which enhance the effects of the low-level laser.
This ability of coMra to provide energy to immune cells is the basis for treatment of viral infections such as COVID-19 as well as a wide range of health conditions. This is not limited to SARS-Cov-2 but has also been observed in the SARS-CoV outbreak in 2003, H1N1 in 2009, MERS-CoV in 2013. The paper concludes that for those individuals who are recovering after COVID-19, coMra may also offer significant benefits in terms of regeneration of organs and systems that have sustained inflammation-related damage.